Bisolvon

Selected form

Bromhexine

Method of action: Antitussive, Cough And Cold Preparations, Expectorant, Increasing The Production Of Surfactant, Mucolytic, Secretolitic, Secretory

Treatment option: Asthma, Bronchitis, Bronchiectasis, Pneumoconiosis, Pneumonia, Crush Injury, Tuberculosis, Pulmonary Tuberculosis, Emphysema

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bisolvon

Property	Description
Active ingredient	Bromhexine hydrochloride
Form	Tablets, oral solution (elixir/syrup)
Pharmacological class	Mucolytic agent, Secretolytic agent
Common use	Relief of congested airways
Origin	Synthetic benzylamine derivative

What is the Pharmacological Class and Purpose of Bisolvon?

Bisolvon is a medicine containing the active ingredient Bromhexine hydrochloride, and is primarily classified as a mucolytic agent and secretolytic agent. Its general purpose is to aid the respiratory system by specifically targeting thick, tenacious phlegm and facilitating its removal from the airways, a function that contributes to its recognition on international lists of essential medicines. As a secretolytic agent, Bromhexine helps in easing the difficulty of expectorating thick secretions. This means the medicine is clinically recognized for helping to clear the throat and chest when mucus is hard to shift.

As a potent mucolytic agent, its core function is to actively break down the complex structure of the sticky secretions found in the bronchial tubes. This targeted mechanism differentiates it from simpler demulcents. Its typical use is intended for situations where an individual experiences discomfort due to retained, excessively viscous mucus, requiring active support for airway clearance.

Composition, Origin, and Available Forms

The active compound, Bromhexine hydrochloride, is chemically identified as a synthetic benzylamine derivative, meaning it is a substance chemically manufactured in a laboratory rather than being derived from a natural source. It is consistently formulated as a single-ingredient product, ensuring its pharmacological effect is solely attributable to the action of Bromhexine. Notably, Bisolvon is frequently marketed internationally with specific patient groups in mind, such as having distinct formulations optimized for adults versus children.

This medication is presented in multiple common pharmaceutical preparations to accommodate varying patient needs, including solid tablets and various liquid forms, such as the oral solution or elixir. Across all these forms, the principal route of administration is oral, allowing the active ingredient to enter the bloodstream and exert its intended systemic effect on mucus throughout the entire respiratory tract.

Regulatory References

WHO Model List

What side effects are possible with Bisolvon?

Bisolvon, which contains the active ingredient bromhexine hydrochloride, is generally well-tolerated, but like all medications, it can cause side effects. Awareness of these potential effects and relevant warnings is important for safe use.

Common Side Effects

Side effects are usually mild and may resolve on their own. The most commonly reported issues relate to the gastrointestinal tract:

Gastrointestinal: Nausea, vomiting, diarrhea, upper abdominal pain, and other mild stomach discomfort.
Other: Headache, dizziness, and sweating.

Serious Side Effects and Warnings

Hypersensitivity and Allergic Reactions

Severe allergic reactions are rare but require immediate medical attention. Symptoms may include rash (including hives/urticaria), itching, swelling of the face, lips, tongue, or throat (angioedema), and difficulty breathing (bronchospasm).

Severe Skin Reactions

There have been very rare reports of severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), associated with mucolytics like bromhexine. If new skin lesions or mucosal lesions appear, discontinue the medication immediately and seek medical advice.

Precautions and Contraindications

Bisolvon should be used with caution in patients with a history of gastric or peptic ulcers due to the drug's mucolytic action, which may affect the gastric mucosal barrier. Caution is also advised in patients with severe liver or kidney impairment, as clearance of the drug may be reduced. Due to the potential for dizziness, patients should avoid driving or operating machinery until they know how the medicine affects them. It is generally not recommended for use during breastfeeding.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Bisolvon (Bromhexine hydrochloride) as one of low toxicity, with a wide therapeutic margin.

Documented Manifestations

Symptoms: Regulatory sources state that no specific overdose symptoms have been reported in humans. Clinical manifestations are generally consistent with the known adverse effects of the medicine, which may include gastrointestinal disturbances such as nausea, vomiting, diarrhoea, and upper abdominal pain.
Physiological Findings: Other potential findings include a transient rise in serum aminotransferase values and an undesirable increase in the volume of bronchial secretions.
Serious Outcomes: The regulatory summaries do not document specific serious or life-threatening outcomes directly related to Bromhexine overdose.

Mandated Emergency Action

Urgent Care Required: Regulatory labeling mandates that individuals seek immediate medical attention and contact a Poisons Information Centre or emergency services for advice on management in all cases of suspected overdose.
Help-Seeking Trigger: This immediate action is necessary even if the individual has no immediate signs of discomfort or poisoning.
Management: Treatment is symptomatic and supportive. The regulatory information indicates that no specific antidote is known for Bromhexine hydrochloride overdose.

Therapeutic Uses of Bisolvon

Bisolvon is used to provide symptomatic relief and supportive therapeutic benefit across domains involving excessive and problematic mucus production in the respiratory tract. It is commonly applied in settings where symptoms create noticeable interference with daily comfort, such as during episodes of the common cold, influenza, or acute bronchitis.

The medicine is used for managing symptoms of excessive mucus production. This primarily helps address the cluster of symptoms associated with a productive cough that is difficult to manage due to thick, viscous, or sticky phlegm. It is relevant for easing the removal of secretions from the respiratory tract.

The medication is also relevant across conditions characterized by episodic or fluctuating symptom patterns, particularly for managing the ongoing burden of secretions in chronic illnesses like Chronic Bronchitis and other bronchopulmonary diseases. The goal is to contribute to easing the overall symptom load and support patients in maintaining functional stability during periods of heightened symptoms.

“This supportive therapy may assist with making the patient’s productive cough feel easier, which contributes to more comfortable airway management.”

Quick Fact: Relief for Viscid Secretions
Bisolvon is generally applied when the thickness of the mucus is a significant factor interfering with natural airway clearance. It supports the patient and may contribute to easier expulsion.

Regulatory References

Australian Therapeutic Goods Administration (TGA) Product Information

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Bisolvon (Bromhexine)

Official regulatory documents define the populations permitted to use Bisolvon, as well as those for whom use is contraindicated or restricted.

Absolute Contraindications	Official Restriction
Known hypersensitivity to bromhexine or excipients.	Children under 2 years of age (contraindicated or not recommended).
Hereditary intolerance to fructose or galactose (formulation-dependent).	Severe renal or hepatic failure (use with caution).
	History of peptic ulceration (use with caution).

Age-Group Eligibility: The medicine is generally established for use in adults and adolescents (typically 12 years and older). Use in children 6 to 11 years is often subject to the advice of a healthcare professional. Use in children under 2 years is contraindicated by multiple regulatory bodies.

Pregnancy and Lactation: Use during pregnancy is typically not recommended, especially during the first trimester. Due to the potential for excretion in breast milk, use while breastfeeding is also not recommended according to labeling.

Conditional Use: Patients with severe liver disease or severe kidney failure are advised to use with caution, as are those with a history of stomach or duodenal ulcers.

What should I know about interactions with other medicines?

The interaction profile for Bisolvon (Bromhexine hydrochloride) is characterized by a high degree of specificity regarding its co-administration with other medicines and products, as documented by official regulatory sources.

Drug and Substance Interactions

Officially documented interactions are primarily related to specific antibiotic classes. Co-administration of Bromhexine hydrochloride with antibiotics such as amoxicillin, erythromycin, oxytetracycline, and tetracyclines results in a measurable increase in the antibiotic's concentration specifically within the patient's sputum and bronchopulmonary secretions. This includes other related agents such as chloramphenicol, ampicillin, and spiramycin.

Pharmacokinetic Considerations

In terms of systemic exposure, regulatory data confirm that co-administration with food intake tends to increase the plasma concentrations of Bromhexine. No mandatory separation times or timing-based administration rules are explicitly documented for co-administered medicines or for food.

Absence of Documented Metabolic or Contraindicated Interactions

Regulatory labels confirm that no formal combinations are classified as contraindicated due to interaction risk. Furthermore, assessments of metabolic potential indicate that relevant interactions with substrates of the major metabolizing enzymes, such as CYP 450 2C9 or 3A4, are considered unlikely based on the drug's established metabolic pattern. This profile indicates a minimal risk for systemic drug-drug interactions through common metabolic pathways.

Mechanism of Action

Molecular Mechanism of Action

Bisolvon (bromhexine) functions as a secretolytic agent, modifying the physical properties of bronchial secretions to facilitate their transport. The primary molecular action involves promoting the hydrolytic depolymerization of long-chain acid mucopolysaccharide fibers and mucoproteins. This biochemical breakdown reduces the molecular weight and complexity of the mucus, decreasing its viscosity and elasticity.

Simultaneously, the drug acts on the serous glands within the respiratory tract, stimulating the synthesis and secretion of low-viscosity fluid (sialomucins). This influx of fluid contributes to the dilution and hydration of the mucus blanket. The resultant lower-viscosity secretions, combined with a secretomotoric effect that increases ciliary activity, enhances the function of the mucociliary escalator. This systemic physiological modulation facilitates the movement and clearance of the liquefied secretions from the bronchial passages via the cough reflex.

Dosage and Administration Information

Bisolvon (bromhexine hydrochloride) use is governed by standardized instructions detailing administration route, dose frequency, and course duration.

Administration Route and Timing

The primary route is oral administration, available as tablets, oral solution, and syrup. In specific clinical scenarios, administration may occur via intramuscular (IM) or intravenous (IV) injection, typically for severe cases in a hospital setting. The medication may be taken with or without food.

Official Dosing Regimens

Administration is generally scheduled multiple times per day, with dosages differentiated by age, as documented in prescribing information.

Population	Standard Dosing Regimen	Maximum Dosing Rule (Oral)
Adults & Adolescents (ge 12 years)	8 mg three times daily (TID)	May be increased up to 16 mg TID for the first seven days.
Children 6–11 years	8 mg three times daily (TID)	Follows standard dose unless otherwise advised.
Children 2–5 years	4 mg twice daily (BID) or three times daily (TID)	Based on specific product label.

Procedural Conditions and Duration

For liquid forms, accurate administration requires using the measuring device supplied with the product. Use is restricted to short-term courses, generally not exceeding 7 to 14 days without the direction of a healthcare professional. High-level caution is advised for patients with severe liver or renal impairment due to potential changes in drug clearance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bisolvon

Evidence for Mucolytic Support in Respiratory Conditions

Research has explored the role of Bisolvon (Bromhexine) in conditions characterized by fluctuating or episodic manifestations involving excessively thick or sticky phlegm. Research examined the application of Bisolvon in study settings focusing on both acute respiratory conditions and conditions involving periods of heightened symptoms such as chronic bronchitis. Studies typically consisted of short-term, randomized controlled trials (RCTs) and double-blind, placebo-controlled trials, primarily including adult patient populations.

The trials evaluated several key outcomes related to physical discomfort, specifically focusing on the properties of the phlegm itself. Researchers examined changes in how thick and sticky the secretions were, the overall volume, and patient-reported outcomes describing perceived discomfort, such as the difficulty of clearing the chest and throat.

Research on Symptom-Specific Outcomes and Uncertainty

Studies specifically explored outcomes capturing phases of heightened symptom activity, such as severe or persistent coughing due to phlegm buildup. For acute conditions, data show patterns related to the time required for symptoms to evolve in some trials, but many systematic reviews reported that active treatments appear to only show a small measured difference compared to a placebo.

Evidence quality varies across studies, as many primary trials were conducted decades ago and sample sizes were modest. Findings were mixed across various studies, especially when comparing the medicine to a placebo for acute cough symptoms.

The Landscape of Follow-up Studies and Specific Groups

The evidence base was observed in trials relevant in trials assessing short-term or episodic symptom patterns. The majority of the studies conducted had follow-up durations that were limited, typically ranging from just one to three weeks. Limited information for long-term outcomes means that the durability of observed patterns is not well established by the existing research.

Data for certain groups remain insufficient. For instance, few data are available from large-scale, methodologically robust, randomized controlled trials specifically in pediatric populations. The research does not determine the effects of the medicine in pregnant populations or those with certain severe comorbidities, meaning subgroup findings are uncertain for these groups.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Bisolvon (FAQ)

Q: Can I take Bisolvon while I am pregnant or breastfeeding?

Official product information states that use during pregnancy is generally avoided as a precautionary measure, due to limited safety data. The product label states that use is not recommended while breastfeeding because the excretion of the active ingredient in breast milk cannot be ruled out.

Q: Can I take Bisolvon with food?

Official regulatory documents indicate that the medicine may be taken with or without food. While taking it with food may increase the plasma concentration of bromhexine, the product label does not require mandatory separation times for this reason.

Q: Is it safe to drive after taking Bisolvon?

Studies specifically addressing the effect of Bisolvon on driving ability have not been performed. Due to the potential for side effects like dizziness and headache, the official product label states that individuals should avoid driving or operating machinery until they know how the medicine affects them.

Q: How long does it take for Bisolvon to work?

Regulatory documents indicate that the active ingredient is rapidly absorbed after being taken. Peak concentrations in the bloodstream have been observed to occur approximately one hour after a dose is taken.

Q: Is Bisolvon a cough suppressant?

No, Bisolvon is classified as a mucolytic and secretolytic agent, not a cough suppressant. Its action, as a secretolytic and mucolytic, is to break down and thin thick mucus to facilitate expectoration, which supports the clearance function of the cough reflex.

How should Bisolvon be stored and disposed of?

How to Store and Dispose of Bisolvon?

The storage and disposal of Bisolvon (bromhexine hydrochloride) must follow specific regulatory requirements to maintain product stability and safety.

Mandatory Storage Conditions

Most Bisolvon formulations must be stored below 25°C in a cool, dry place, protected from moisture, direct heat, or sunlight. The medicine should not be kept in environments like bathrooms, cars, or near sinks. All products must be stored out of the sight and reach of children.

Stability and Disposal Rules

Use of the medicine is not permitted after the expiry date. The oral solution should be kept in its original container and typically must be discarded if opened for more than 12 months. Unused or expired Bisolvon must not be thrown into household waste or wastewater. Instead, regulatory instructions require returning the product to a pharmacy for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.